drugset / Trial / NCT00751517

Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides

NCT00751517 ↗

Phase 2 Unknown University of Parma
RandomizedParallel-groupOpen-labelTreatment

Summary

The Systemic Necrotizing Vasculitides (SNV) encompass a group of rare diseases which include Wegener's Granulomatosis (WG), Churg-Strauss Syndrome (CSS), Microscopic polyangiitis (MPA)and Polyarteritis nodosa (PAN). Common histological findings are inflammation with fibrinoid necrosis of the small vessels and sporadic or absent immune-deposits. The gold standard therapy for SNV is currently represented by the association of Cyclophosphamide and Prednisone. The limits of this approach are the high frequency of recurrent disease and an increased incidence of malignancy and infections. The aim of the present study is to compare the efficacy of Methotrexate vs Cyclophosphamide for Remission Maintenance in SNV.

Timeline

Start
—
Primary completion
—
Completion
—

Outcome

Missed primary endpoint

paper Relapse frequencies at months 12 and 24 after randomisation were not different between the two groups (p = 1.00 and 1.00). PMID 29016646 ↗

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclophosphamide Other / unclassified — —
Subject Methotrexate Small molecule — —